Neuberger Berman Group
RPRX icon

Neuberger Berman Group’s Royalty Pharma RPRX Stock Holding History

Neuberger Berman Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Buy
54,550
+3,956
+8% +$206K ﹤0.01% 1162
2026
Q1 		$2.43M Sell
50,594
-10,487
-17% -$459K ﹤0.01% 1127
2025
Q4 		$2.36M Buy
61,081
+19,439
+47% +$741K ﹤0.01% 1129
2025
Q3 		$1.47M Buy
41,642
+8,052
+24% +$292K ﹤0.01% 1245
2025
Q2 		$1.21M Buy
33,590
+3,847
+13% +$127K ﹤0.01% 1292
2025
Q1 		$926K Buy
29,743
+13,249
+80% +$420K ﹤0.01% 1346
2024
Q4 		$421K Buy
16,494
+1,882
+13% +$49.9K ﹤0.01% 1569
2024
Q3 		$413K Buy
14,612
+6,839
+88% +$189K ﹤0.01% 1575
2024
Q2 		$205K Sell
7,773
-13,563
-64% -$376K ﹤0.01% 1757
2024
Q1 		$648K Sell
21,336
-16,948
-44% -$500K ﹤0.01% 1413
2023
Q4 		$1.08M Sell
38,284
-492,550
-93% -$13.5M ﹤0.01% 1464
2023
Q3 		$14.4M Buy
530,834
+1,881
+0.4% +$55.9K 0.01% 665
2023
Q2 		$16.3M Sell
528,953
-7,014
-1% -$238K 0.01% 647
2023
Q1 		$19.3M Sell
535,967
-7,494
-1% -$278K 0.02% 632
2022
Q4 		$21.5M Buy
543,461
+4,318
+0.8% +$180K 0.02% 598
2022
Q3 		$21.7M Buy
539,143
+109
+0% +$4.66K 0.02% 594
2022
Q2 		$22.7M Buy
539,034
+154,190
+40% +$6.32M 0.02% 597
2022
Q1 		$15M Buy
+384,844
New +$15.1M 0.01% 730
2020
Q3 		– Sell
-10,000
Closed -$486K – 1660
2020
Q2 		$486K Buy
+10,000
New +$495K ﹤0.01% 1288

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's RPRX Position: Q2 2026 in Review

Neuberger Berman Group increased its Royalty Pharma (RPRX) stake by 7.8% in Q2 2026, buying an estimated $206K and bringing the position to 54,550 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1162.

Neuberger Berman Group first reported a position in RPRX in Q2 2020 and has held it in 19 quarters since. The position peaked at $22.7M in Q2 2022. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Neuberger Berman Group held 54,550 shares of Royalty Pharma worth $3.06M as of Q2 2026.
  • Neuberger Berman Group bought 3,956 Royalty Pharma shares in Q2 2026, an estimated $206K.
  • Royalty Pharma made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1162 holding.
  • Neuberger Berman Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 19 quarters since.
  • Neuberger Berman Group's Royalty Pharma position peaked at $22.7M in Q2 2022.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.